Eplereone

Phase 1Small molecule

AAssiut University

Eplereone is one of 23 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Atrial FibrillationPhase 1

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Anticoagulants

Sanofi

Preclinical

2 2

Direct Anticoagulant

Bayer

Preclinical

1 3

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 4

Statin

Bristol-Myers Squibb

Preclinical

1 5

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 6

Magnesium SO4

HHospital de Base

Preclinical

2 7

Medication

NNYU Langone Health

Preclinical

1 8

Bupivacain

IIstanbul University

Preclinical

1 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

Recruiting·—·Phase 1·NCT06556732·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eplereone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eplereone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eplereone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAssiut University

Eplereone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News